Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
- Successful clinical trial for re-engineered UQ vaccine - 28th November 2023
- The widening the gap between the “haves and have-nots” - 28th November 2023
- Horrifying hand washing habits - 28th November 2023